MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic ...
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision peptide medicines for endocrine and metabolic disorders. The company was founded in 2018, initially as MBX Biosciences LLC in Indiana, and later converted to a Delaware corporation. It is headquartered at 11711 N. Meridian Street in Carmel, Indiana. MBX completed its initial public offering on September 13, 2024, and its common stock trades on the Nasdaq Global Select Market under the ticker MBX.
The company’s development strategy centers on engineered peptide prodrugs and long-acting peptide therapies intended to provide more precise, durable, and convenient treatment than conventional hormone or metabolic medicines. Its most advanced disclosed program is MBX 2109, a parathyroid hormone peptide prodrug being evaluated in Phase 2 clinical trials. The program is intended as a long-duration hormone-replacement treatment for people with chronic hypoparathyroidism, a disorder in which the body does not produce sufficient parathyroid hormone and therefore has difficulty regulating calcium and phosphate levels. A successful therapy could potentially address limitations associated with frequent dosing and the need for ongoing disease management.
MBX is also developing MBX 1416, a prolonged-action glucagon-like peptide-1, or GLP-1, receptor antagonist. This program is in Phase 1 clinical development for post-bariatric hypoglycemia, a condition that can occur after weight-loss surgery and cause episodes of abnormally low blood glucose. In addition, MBX 4291 is an investigational obesity candidate in IND-enabling studies. It is described as a potent, long-acting prodrug designed to co-agonize the GLP-1 and glucose-dependent insulinotropic polypeptide, or GIP, receptors, with the goal of treating obesity and associated metabolic comorbidities.
As a clinical-stage company, MBX does not yet have an established commercial product or meaningful recurring product revenue based on the supplied trailing information. Its financial profile therefore reflects research and development spending, clinical-trial costs, regulatory work, manufacturing preparation, and general corporate expenses rather than product sales. The supplied data show approximately $3.23 billion in market capitalization, approximately $3.18 billion in enterprise value, negative free cash flow of about $105.8 million, and a current ratio of approximately 18.1. These figures indicate substantial liquidity relative to short-term liabilities, but also the cash-burning profile typical of a biotechnology company progressing through clinical development. The company reported approximately 63 full-time employees, placing it in the 0-100 employee category. Steve Hoerter serves as Chairman and Chief Executive Officer, supported by a leadership team that includes Chief Medical Officer Sam Azoulay and Chief Business Officer Karen Basbaum. MBX’s principal long-term objective is to advance its peptide pipeline through clinical validation, regulatory approval, and eventual commercialization while addressing significant unmet needs in endocrine and metabolic medicine.
